International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8330211
Original Article
APLS and Recurrent Pregnancy Loss- A Case Series
 ,
 ,
Published
Aug. 31, 2023
Abstract

Objectives: This is a Case Series of 3 patients of APLS with varied presentations who were diagnosed and improved following treatment. Antiphospholipid antibody syndrome is a heterogenous autoantibody mediated acquired thrombophilia, which is associated with severe life-threatening complications during pregnancy.

CASES: Case 1: A 29 yr old female presented to us with Generalised edema over body and shortness of breath over the past 2 months, with severe anemia and a history of 2 pregnancy losses at 4 weeks and at 10 weeks of pregnancy. On evaluation, she was diagnosed as SLE with Class V Lupus Nephritis and Secondary APLS.

Case 2: A 35 yr old female presented with multiple episodes of GTCS, had a history of 3 abortions at 4, 6 and 10 weeks of pregnancy, and had an episode of Left sided Hemiparesis 2 years back. MRI was suggestive of chronic venous infarcts and she was diagnosed as a case of Primary APLS.

Case 3: A 20 yr old primigravida presented with Antepartum eclampsia, she suffered from an Intrauterine Death and post LSCS, she developed sudden onset weakness of Left side of her body. On evaluation for hypercoagulable state, was diagnosed with APLS.

Results and Conclusions: Clinicians should have a high index of suspicion of APLS in patients with history of recurrent abortions or Intra uterine death with unexplained cause.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
1037 Views
131 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved